VRN 04
Alternative Names: VRN-04Latest Information Update: 28 Feb 2024
At a glance
- Originator Voronoi
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics
- Mechanism of Action RIPK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Multiple sclerosis
- No development reported Acute lung injury; Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Acute-lung-injury in South Korea (PO)
- 28 Feb 2024 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in South Korea (PO)
- 28 Feb 2024 No recent reports of development identified for preclinical development in Psoriasis in South Korea (PO)